BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32399569)

  • 1. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
    Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
    Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
    O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
    Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
    Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
    World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
    Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.
    Bowman CJ; Zhang R; Balitzer D; Wang D; Rabinovitch PS; Kővári BP; Mattis AN; Kakar S; Lauwers GY; Choi WT
    Mod Pathol; 2021 Oct; 34(10):1889-1900. PubMed ID: 34108638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
    Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
    Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study.
    Sinh P; Anaparthy R; Young PE; Gaddam S; Thota P; Balasubramanian G; Singh M; Higbee AD; Wani S; Gupta N; Rastogi A; Mathur SC; Bansal A; Horwhat JD; Cash BD; Falk GW; Lieberman DA; Vargo JJ; Sampliner RE; Sharma P
    Endoscopy; 2015 Aug; 47(8):669-74. PubMed ID: 25910065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.
    Krishnamoorthi R; Lewis JT; Krishna M; Crews NJ; Johnson ML; Dierkhising RA; Ginos BF; Wang KK; Wolfsen HC; Fleischer DE; Ramirez FC; Buttar NS; Katzka DA; Iyer PG
    Am J Gastroenterol; 2017 Jun; 112(6):867-873. PubMed ID: 28374813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study.
    Phillips R; Januszewicz W; Pilonis ND; O'Donovan M; Sawas T; Katzka DA; Fitzgerald RC; di Pietro M
    Gastrointest Endosc; 2021 Aug; 94(2):263-270.e2. PubMed ID: 33548281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.